Cotadutide
Fat LossInvestigational dual incretin/glucagon agonistEmerging
AstraZeneca GLP-1/glucagon receptor dual agonist studied for NASH and type 2 diabetes. Clinical development has been mixed; not FDA-approved.
For research use only.
Key Facts
- CAS
- 1686108-82-2
- Molecular Weight (MW)
- —
- Half-life
- ~13 hours (sc) in human PK models
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Daily or per protocol
- Last updated
- 8/23/2026
- Targets
- GLP-1 receptorGlucagon receptor
Overview
AstraZeneca GLP-1/glucagon receptor dual agonist studied for NASH and type 2 diabetes. Clinical development has been mixed; not FDA-approved.
Protocol
- Dosage Range
- Per trial protocol
- Frequency
- Daily or per protocol
- Cycle
- Per study
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
Science
Mechanism of Action
Balanced GLP-1R and GCGR agonism intended to reduce appetite and increase hepatic energy expenditure / glycogenolysis versus GLP-1 alone.
Targets
GLP-1 receptorGlucagon receptor
Studies
- Cotadutide phase 2a NASH/T2D— Journal/year not available
Benefits
NASH and diabetes research candidate
Potential Side Effects
- GI adverse events
- Increased heart rate (glucagon class)
References
- PMID 32816916External link · Year —